EP4 prostanoid receptor-mediated vasodilatation of human middle cerebral arteries

British Journal of Pharmacology

Volumn 141, Issue 4, 2004, Pages 580-585

  Davis, Richard J ^a   Murdoch, Colin E ^a   Ali, Mozam ^a   Purbrick, Stuart ^a   Ravid, Rivka ^b   Baxter, Gordon S ^c   Tilford, Nick ^c   Sheldrick, Robert L G ^a   Clark, Kenneth L ^a   Coleman, Robert A ^a  

^a Pharmagene Laboratories   (United Kingdom)

^b NETHERLANDS BRAIN BANK   (Netherlands)

^c BioWisdom Ltd   (United Kingdom)

Author keywords

EP4 receptor; Human middle cerebral artery; Migraine; Prostaglandin E2

Indexed keywords

11 DEOXYPROSTAGLANDIN E1; 15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; 7 [5 (4 BIPHENYLYLMETHOXY) 2 MORPHOLINO 3 OXOCYCLOPENTYL] 4 HEPTENOIC ACID; BUTAPROST; CICAPROST; ILOPROST; INDOMETACIN; INOSITOL PHOSPHATE RECEPTOR; INOSITOL PHOSPHATE RECEPTOR AGONIST; PHENYLEPHRINE; PROSTAGLANDIN D2; PROSTAGLANDIN DP RECEPTOR AGONIST; PROSTAGLANDIN E1 DERIVATIVE; PROSTAGLANDIN E2; PROSTAGLANDIN E2 AGONIST; PROSTAGLANDIN E4 RECEPTOR ANTAGONIST; PROSTAGLANDIN F2 ALPHA; PROSTAGLANDIN FP RECEPTOR AGONIST; PROSTAGLANDIN RECEPTOR; PROSTAGLANDIN TP RECEPTOR; PROSTAGLANDIN TP RECEPTOR ANTAGONIST; PROSTANOID EP4 RECEPTOR; PROSTANOID RECEPTOR; UNCLASSIFIED DRUG; VAPIPROST; BIPHENYL DERIVATIVE; DRUG DERIVATIVE; EP4 RECEPTOR; HEPTANOIC ACID DERIVATIVE; PROSTAGLANDIN E RECEPTOR; PROSTAGLANDIN EP2 RECEPTOR; VASOCONSTRICTOR AGENT; VASODILATOR AGENT;

ADULT; AGED; ARTICLE; BRAIN BLOOD VESSEL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENCY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MIDDLE CEREBRAL ARTERY; MIGRAINE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; SALIVA ANALYSIS; VASODILATATION; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; IN VITRO STUDY; MIDDLE AGED; MUSCLE CONTRACTION; PHYSIOLOGY; VASCULAR SMOOTH MUSCLE;

15-HYDROXY-11 ALPHA,9 ALPHA-(EPOXYMETHANO)PROSTA-5,13-DIENOIC ACID; AGED; AGED, 80 AND OVER; BIPHENYL COMPOUNDS; DINOPROSTONE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEPTANOIC ACIDS; HUMANS; ILOPROST; INDOMETHACIN; MALE; MIDDLE AGED; MIDDLE CEREBRAL ARTERY; MUSCLE CONTRACTION; MUSCLE, SMOOTH, VASCULAR; PHENYLEPHRINE; RECEPTORS, PROSTAGLANDIN E; VASOCONSTRICTOR AGENTS; VASODILATION; VASODILATOR AGENTS;

EID: 4944238567     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0705645     Document Type: Article

References (48)

1. ARBAB, M.A., DELGADO, T., WIKLUND, L. & SVENDGAARD, N.A. (1988). Brain stem terminations of the trigeminal and upper spinal ganglia innervation of the cerebrovascular system: WGA-HRP transganglionic study. J. Cereb. Blood Flow Metab., 8, 54-63.
2. ARUNLAKSHANA, O. & SCHILD, H.O. (1959). Some quantitative use of drug antagonists. Br. J. Pharmacol. Chemother., 257, 48-58.
3. 2 receptor subtype 4 mRNA in human mononuclear Jurkat and KM-3 cells and coexpression of subtype 4 and 2 mRNA in U-937 cells. FEBS Lett., 394, 39-43.
4. BOIE, Y., STOCCO, R., SAWYER, N., SLIPETZ, D.M., UNGRIN, M.D., NEUSCHAFER-RUBE, F., PUSCHEL, G.P., METTERS, K.M. & ABRAMOVITZ, M. (1997). Molecular cloning and characterisation of the four rat prostaglandin EP receptor subtypes. Eur. J. Pharmacol., 340, 227-241.
5. 2 is attributed to sensitisation of CGRP-containing sensory nerves. Gastroenterology, 120, 134-143.
6. BOLAY, H., REUTER, U., DUNN, A.K., HUANG, Z., BOAS, D.A. & MOSKOWITZ, M.A. (2002). Intrinsic brain activity triggers trigeminal meningeal afferents in a migraine model. Nat. Med., 8, 136-142.
7. 4 receptor. Am. J. Physiol., 270, F485-F493.
8. BUZZI, M.G., CARTER, W.B., SHIMIZU, T., HEATH, H. & MOSKOWITZ, M.A. (1991). Dihydroergotamine and sumatriptan attenuate levels of CGRP in plasma in rat superior sagittal sinus during electrical stimulation of the trigeminal ganglion. Neuropharmacology, 30, 1193-1200.
9. CARLSON, L.A., EKELUND, L.G. & ORÖ, L. (1968). Clinical and metabolic effects of different doses of prostaglandin E1 in man. Prostaglandin and related factors. Acta Med. Scand., 83, 423-430.
10. CODISPOTI, J.R., PRIOR, M.J., FU, M., HARTE, C.M. & NELSON, E.B. (2001). Efficacy of non-prescription doses of ibuprofen for treating migraine headache. A randomised controlled trial. Headache, 41, 665-679.
11. COLEMAN, R.A., GRIX, S.P., HEAD, S.A., LOUTTIT, J.B., MALLET, A. & SHELDRICK, R.L. (1994b). A novel inhibitory prostanoid receptor in piglet saphenous vein. Prostaglandins, 47, 151-168.
12. COLEMAN, R.A., SMITH, W.L. & NARUMIYA, S. (1994a). VIII. Internation Union of Pharmacology Classification of prostanoid receptors: properties, distribution, and structure of the receptors and their subtypes. Pharmacol. Rev., 46, 205-229.
13. 4 receptor. Br. J. Pharmacol., 130, 1919-1926.
14. DIB, M., MASSIOU, H., WEBER, M., HENRY, P., GARCIA-ACOSTA, S. & BOUSSER, M.G. (2002). Efficacy of oral ketoprofen in acute migraine: a double-blind randomised clinical trial. Neurology, 58, 1660-1665.
15. DIENER, H.C. (1999). Efficacy and safety of intravenous acetylsalicylic acid lysinate compared to subcutaneous sumatriptan and parenteral placebo in the acute treatment of migraine. A double-blind, double-dummy, randomised, multicenter, parallel group study. Cephalagia, 19, 581-588.
16. 2 following electrical and chemical stimulation in vitro. Neuroscience, 89, 901-907.
17. EBERSBERGER, A., SCHAIBLE, H.G., AVERBECK, B. & RICHTER, F. (2001). Is there a correlation between spreading depression, neurogenic inflammation, and nociception that might cause migraine headache? Ann. Neurol., 49, 7-13.
18. FRIESE, N., DIOP, L., CHEVALIER, E., ANGEL, F., RIVIERE, P.J. & DAHL, S.G. (1997). Involvement of prostaglandins and CGRP-dependent sensory afferents in peritoneal irritation-induced visceral pain. Regul. Pept., 70, 1-7.
19. GAO, I.K., SCHOLZ, P., BOEHME, M.W.J., NORDEN, C. & LEMMEL, E.-M. (2002). A 7-day oral treatment of patients with active rheumatoid arthritis using the prostacyclin analog iloprost: cytokine modulation, safety and clinical effects. Rheumatol. Int., 22, 45-51.
20. GARDINER, P.J. (1986). Characterisation of prostanoid relaxant/ inhibitory receptor using a highly selective agonist, TR4979. Br. J. Pharmacol., 87, 45-56.
21. GOADSBY, P.J. & EDVINSSON, L. (1993). The trigeminal system and migraine: studies characterising cerebrovascular and neuropeptide changes seen in man and cat. Ann. Neurol., 33, 48-56.
22. HILDEBRAND, M. (1997). Pharmacokinetics and tolerability of oral iloprost in thromboangiitis obliterans patients. Eur. J. Pharmacol., 53, 51-56.
23. HUA, X.Y., JINNO, S., BACK, S.M., TAM, E.K. & YAKSH, T.L. (1994). Multiple mechanisms for the effects of capsaicin, bradykinin and nicotine on CGRP release from tracheal afferent nerves: role of prostaglandins, sympathetic nerves and mast cells. Neuropharmacology, 33, 1147-1154.
24. HUMPHREY, P.P. & FENIUK, W. (1991). Mode of action of the anti-migraine drug sumatriptan. Trends Pharmacol. Sci., 12, 444-446.
25. JENKINS, D.W., FENIUK, W. & HUMPHREY, P.P.A. (2001). Characterisation of the prostanoid receptor types involved in mediating calcitonin gene-related peptide release from cultured rat trigeminal neurones. Br. J. Pharmacol., 134, 1296-1302.
26. KELLSTEIN, D.E., LIPTON, R.B., GEETHA, R., KORONKIEWICZ, K., EVANS, F.T., STEWART, W.F., WILKES, K., FUREY, S.A., SUBRAMANIAN, T. & COOPER, S.A. (2000). Evaluation of a novel solubilised formulation of ibuprofen in the treatment of migraine headache: a randomised, double-blind, placebo-controlled, dose-ranging study. Cephalagia, 20, 223-243.
27. KIRIYAMA, M., USHIKUBI, F., MOBAYASHI, T., HIRATA, M., SUGIMOTO, Y. & NARUMIYA, S. (1997). Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells. Br. J. Pharmacol., 122, 217-224.
28. KOBARI, M., FUKUUCHI, Y., TOMITA, M., TANAHASHI, N., KONNO, S. & TAKEDA, H. (1993). Effects of sumatriptan on the cerebral intraparenchymal microcirculation in the cat. Br. J. Pharmacol., 110, 1445-1448.
29. 2 receptor blocking drug on platelets and vascular and airways smooth muscle, in vitro. Br. J. Pharmacol., 97, 783-794.
30. 2. Mol. Pharmacol., 60, 36-41.
31. 2. Mol. Pharmacol., 64, 192.
32. MAY, A., BUCHEL, C., TURNER, R. & GOADSBY, P.J. (2001). Magnetic resonance angiography in facial and other pain: neurovascular mechanisms of trigeminal sensation. J. Cereb. Blood Flow Metab., 21, 1171-1176.
33. MOSKOWITZ, M.A. (1993). Neurogenic versus vascular mechanisms of sumatriptan and ergot alkaloids in migraine. Trends Pharmacol. Sci., 13, 307-377.
34. NAKAGOMI, T., KASSELL, N.F., SASAKI, T., LEHMAN, R.M., TORNER, J.C., HONGO, K. & LEE, J.H. (1988). Effects of removal of the endothelium on vasoconstriction in canine and rabbit basilar arteries. J. Neurosurg., 68, 757-766.
35. NATTERO, G., ALLAIS, G., DE LORENZO, C., BENEDETTO, C., ZONCA, M., MELZI, E. & MASSOBRIO, M. (1989). Relevance of prostaglandins in true menstrual migraine. Headache, 29, 232-237.
36. NEGISHI, M., SUGIMOTO, Y. & ICHIKAWA, A. (1995). Molecular mechanisms of diverse actions of prostanoid receptors. Biochem. Biophys. Acta, 1259, 109-120.
37. 2 in the saliva of common migraine patients. Actions of calcium channel blockers. Headache, 29, 498-501.
38. PARANTAINEN, J. (1983). Prostaglandin in alcohol intolerance and hangover. Drug Alcohol Depend., 11, 239-248.
39. PARSONS, A.A. & WHALLEY, E.T. (1989). Effects of prostanoids on human and rabbit basilar arteries pre-contracted in vitro. Cephalalgia, 9, 165-171.
40. PEATFIELD, R.C., GAVEL, M.J. & ROSE, F.C. (1981). The effect of infused prostacyclin in migraine and cluster headache. Headache, 21, 190-195.
41. PRIOR, M.J., COOPER, K.M., MAY, L.G. & BOWEN, D.L. (2002). Efficacy and safety of acetaminophen and naproxen in the treatment of tension-type headache. A randomised, double blind, placebo-controlled trial. Cephalalgia, 22, 232-240.
42. RICH, G., YOBER, E.J., PROKUSKI, L. & MOORE, S.A. (1996). Prostaglandin production in cultured cerebral microvasculature smooth muscle is serum dependent. Am. J. Physiol., 270, C1379-C1387.
43. SARCHIELLI, P., ALBERTI, A., CODINI, M., FLORIDI, A. & GALLAI, V. (2000). Nitric oxide metabolites, prostaglandin and trigeminal vasoactive peptides in internal jugular vein blood during spontaneous migraine attacks. Cephalalgia, 20, 907-918.
44. THE DICLOFENAC-K/SUMATRIPTAN MIGRAINE STUDY GROUP. (1999). Acute treatment of migraine attacks: efficacy and safety of a nonsteroidal anti-inflammatory drug, diclofenac-potassium, in comparison to oral sumatriptan and placebo. Cephalalgia, 19, 232-240.
45. USKI, T., ANDERSSON, K.E., BRANDT, L., EDVINSSON, L. & LIUNOGREN, B. (1983). Responses of isolated feline and human cerebral arteries to prostacyclin and some of its metabolites. J. Cereb. Blood Flow Metab., 3, 238-245.
46. WHALLEY, E.T., SCHILLING, L. & WAHL, M. (1989). Cerebrovascular effects of prostanoids: in vitro studies in feline middle cerebral and basilar artery. Prostaglandins, 38, 625-634.
47. WILLIAMSON, D.J., HARGREAVES, R.J., HILL, R.G. & SHEPHEARD, S.L. (1997). Sumatriptan inhibits neurogenic vasodilation of durai blood vessels in the anaesthetised rat-intravital microscope studies. Cephalalgia, 17, 525-531.
48. 2 release in isolated rat dura. Pain, 97, 259-265.